EN DE
Watch Genomictree Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Genomictree Inc. (228760) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Genomictree Inc. stock KRW 2,983, price KRW 8,840, that is 66.3% below the price, quality 45 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7228760005

GI Genomictree Inc. logo Thin data Nov 6, 2026

Genomictree Inc.

228760 · KQ
Very expensive, weak quality

Our calculation puts a fair price 66% below what the stock costs today.

Low debt
Quality 45/100
Mixed vs. peers (4/8)
Revenue last quarter 51% below a year ago.
Fair value 2,983 KRW · Strongly overvalued
Weak Growth (revenue 3y −49.9 %/yr in KRW)
Negative free cash flow
Narrow moat 12/100
Thin data
Watch Genomictree Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

32,000 KRW 8,560 KRW Fair Value 2,983 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range 8,560 KRW – 32,000 KRW · fair‑value band 1,969 KRW – 3,729 KRW · the 8,840 KRW price screens above the 2,983 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow Genomictree in your weekly email

Every Wednesday you see whether Genomictree is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases.

Show moreShow less

The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients.

It also provides AccuraDTect SARS-CoV-2 RT-qPCR kits, test providers, and nucleic acid transport medium products. The company was founded in 2000 and is headquartered in Daejeon, South Korea.

Stock analysis

Genomictree Inc. (228760) currently trades at 8,840 KRW, while our model-based Fair Value estimate is 2,983 KRW, 66% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the data coverage at low.

Scenario range: 1,969 KRW (bear) to 3,729 KRW (bull), the price of 8,840 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Genomictree Inc. reported revenue of 3.8B KRW in FY2025 versus 5.1B KRW in FY2021, a compound −7.5%/yr. Reported net income was −9.0B KRW in FY2025.

Key figures

Market cap 217B KRW (≈ $162M) Micro · P/S ratio 80.9 · EPS (TTM) −367.76 KRW · Return on equity −7.7% · Return on assets (EBIT) −6.7% (5-year average) · Operating margin −314% · Revenue (TTM) 2.9B KRW · Revenue growth (YoY) −51.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 72% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −66%, 228760 screens richer than that median.

Fair Value models

Bear 1,969 KRW Fair Value 2,983 KRW Bull 3,729 KRW
Price 8,840 KRW · Downside -66.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 1,969 KRW 2,983 KRW 3,729 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 1,969 KRW 2,983 KRW 3,729 KRW 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 45/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 82
Are margins and returns getting better?
Cashflow 14
Do the profits arrive as real cash?
Financial strength 82
Debt, balance sheet and risk of trouble
Investment 63
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 6
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 54
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+59.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−49.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.9%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+55.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,001.6% (2020) → −300.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

228760 screens overvalued: fair value 66% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Genomictree Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 557 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 45 · Above median
Fair Value upside −66.3% · Below median
Profitability
Return on assets −7.4% · Above median
Growth and dividend
Revenue growth (quarter YoY) −51.1% · Bottom 25%
Balance sheet
Debt / equity 0.32× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.88× · Cheaper than median
P/S (12 months) 73.49× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)84 · sector 97
DIVIDEND (yield)0 · sector 21

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $919.96 $1,275 +39% vs 228760
Samsung Biologics Co 207940 1,510,000 KRW 1,661,000 KRW +10% vs 228760
Vertex Pharmaceuticals Incorporated VRTX $550.87 $601.80 +9% vs 228760
WuXi Biologics (Cayman) Inc 2269 HK$48.92 HK$52.38 +7% vs 228760
Genmab A/S GMAB kr 3,661 kr 3,880 +6% vs 228760
argenx SE ARGX $962.27 $908.40 −6% vs 228760
CSL Limited CSL A$200.73 A$181.40 −10% vs 228760
BeOne Medicines AG 6160 HK$248.20 HK$152.80 −38% vs 228760
Celltrion, Inc 068270 210,000 KRW 74,945 KRW −64% vs 228760
Royalty Pharma plc RPRX $68.77 $19.01 −72% vs 228760

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Genomictree Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Genomictree Inc. Fair Value". https://www.fairvalue-calculator.com/stock/228760

Frequently asked questions

Is Genomictree Inc. (228760) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of 2,983 KRW versus a price of 8,840 KRW, about 66% lower (overvalued).
What is the fair value of 228760?
Our model-based fair value for Genomictree Inc. is 2,983 KRW (as of Nov 6, 2026), built from audited fundamentals. The current price: 8,840 KRW.
What is the quality score of 228760?
Genomictree Inc. has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Genomictree Inc. (228760)?
Our model-based price target is the fair value of 2,983 KRW (as of Nov 6, 2026) from 1 valuation models. Cautious scenario 1,969 KRW, optimistic scenario 3,729 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Genomictree Inc. stock forecast for 2026?
Our models put fair value at 2,983 KRW, about 66% lower versus a price of 8,840 KRW (overvalued). Cautious scenario 1,969 KRW, optimistic scenario 3,729 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Genomictree Inc. (228760)?
Genomictree Inc. reported trailing-twelve-month revenue of about 2.9B KRW (latest available figure, as of Nov 6, 2026).
What is the intrinsic value of Genomictree Inc. (228760)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Genomictree Inc. it is 2,983 KRW per share (as of Nov 6, 2026), against a price of 8,840 KRW. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Genomictree Inc. stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 228760 trades above its calculated fair value: price 8,840 KRW, fair value 2,983 KRW, a gap of about −66% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 228760?
No. The price is what the market pays today (8,840 KRW); the fair value is what the company's own numbers justify (2,983 KRW). For Genomictree Inc. the two are 5,857 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Genomictree Inc. worth?
The market values Genomictree Inc. at about 217B KRW (market capitalisation, as of Nov 6, 2026). Per share that is 8,840 KRW; our models calculate a fair value of 2,983 KRW per share.
What do the bullish and bearish scenarios say about 228760?
Our models span a range for Genomictree Inc.: cautious scenario 1,969 KRW, base 2,983 KRW, optimistic 3,729 KRW per share (as of Nov 6, 2026, price 8,840 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Genomictree Inc. (228760)?
Balance-sheet figures for Genomictree Inc. (as of Nov 6, 2026): return on equity −7.7%, debt of 0.32 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is 228760 from its 52-week high?
Genomictree Inc. trades at 8,840 KRW, about 72% below its 52-week high of 32,000 KRW and at the low of 8,800 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 2,983 KRW is for.
Which stocks are comparable to Genomictree Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Genomictree Inc. stock attractive at the current price?
The data as of Nov 6, 2026: price 8,840 KRW, calculated fair value 2,983 KRW (−66%), Quality Score 45/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 228760 calculated?
We run Genomictree Inc. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 2,983 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7% above its aggregate fair value. Genomictree Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Genomictree Inc. (228760)?
The closing price on Nov 9, 2026 was 8,840 KRW. Our model-based fair value is 2,983 KRW, about 66% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Genomictree Inc. right now?
The price sits above even our optimistic bull case (3,729 KRW). The favourable scenario is already priced in. Weak quality (45/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (1,969 KRW to 3,729 KRW) leaves room in how you read the outcome.

Key figures of Genomictree Inc.

How large is the market capitalisation of Genomictree Inc. (228760)?
The market capitalisation of Genomictree Inc. is 217B KRW (≈ $162M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Genomictree Inc. (228760)?
The price-to-sales ratio of Genomictree Inc. is 80.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Genomictree Inc. (228760)?
Earnings per share at Genomictree Inc. are −367.76 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Genomictree Inc. (228760)?
The return on equity (ROE) of Genomictree Inc. is −7.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Genomictree Inc. (228760)?
On an EBIT basis the return on assets of Genomictree Inc. is −6.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Genomictree Inc. (228760)?
The operating margin of Genomictree Inc. is −314% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Genomictree Inc. (228760)?
Revenue at Genomictree Inc. is growing −51.1% versus a year earlier (3y avg −49.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Genomictree Inc. (228760) generate?
The free cash flow of Genomictree Inc. is −12.9B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Genomictree Inc. in the live analysis

One click puts Genomictree Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.